Maravai LifeSciences Holdings, Inc. MRVI

Company Overview

Maravai LifeSciences Holdings, Inc. is a U.S.-based life sciences company that develops and supplies products used in nucleic acid production, biologics safety testing, and drug discovery research. The company primarily serves biotechnology companies, pharmaceutical manufacturers, diagnostic developers, academic institutions, and government research organizations. Maravai operates within the broader biotechnology tools and life sciences services industry, with a focus on enabling the development of vaccines, therapeutics, diagnostics, and advanced therapies. Its business gained significant visibility during the COVID-19 pandemic due to its role in supplying critical components used in mRNA vaccine production.

The company’s primary revenue drivers are products and services sold through its operating brands, particularly in nucleic acid production and biologics safety testing. Maravai’s strategic positioning is tied to its specialization in high-purity nucleic acid materials and proprietary manufacturing capabilities that support regulated biopharmaceutical applications. The company traces its origins to the formation of Maravai in 2014 by GTCR, a private equity firm, through the acquisition and consolidation of life sciences businesses. Maravai later expanded through acquisitions and completed its public listing on Nasdaq in 2020 under the ticker MRVI.